EyePoint Inc. (EYPT)
EyePoint Inc. (EYPT) Stock Price, Analysis & Data
| Bid | 9 |
| Market Cap | 1.13B |
| Revenue (ttm) | 2.79M |
| Net Income (ttm) | -306.64M |
| Beta | 1.74 |
| EPS (ttm) | -3.89 |
| PE Ratio (ttm) | n/a |
| Forward PE | -4.49 |
| P/B (ttm) | 34.17 |
| P/S (ttm) | 418.38 |
| Earnings Date | Nov 11, 2026 |
| Ask | 24 |
| Volume | 2,259,304 |
| Avg. Volume (20D) | 1,435,338 |
| Open | 13.05 |
| Previous Close | 13.05 |
| Day's Range | 13.02 - 13.77 |
| 52-Week Range | 9.65 - 19.11 |
| Analyst | Strong Buy |
| Price Target | 38 (180.86%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About EYPT
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and pat...
Financial Performance
In 2025, EyePoint's revenue was 31.37M, a decrease of -27.5% compared to the previous year's 43.27M. Earnings were -231.96M, an increase of 77.25%.
Financial StatementsAnalyst Forecast
According to 14 analyst ratings, the average rating for EYPT stock is "Strong Buy". The 12-month stock price forecast is 38, which is upside of 180.86% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
